Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Short Interest Update

Fresenius SE & Co. KGaA (OTCMKTS:FSNUYGet Rating) saw a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 23,200 shares, a growth of 107.1% from the March 31st total of 11,200 shares. Based on an average trading volume of 204,200 shares, the short-interest ratio is presently 0.1 days.

Shares of Fresenius SE & Co. KGaA stock opened at $9.04 on Friday. The company has a current ratio of 1.13, a quick ratio of 0.85 and a debt-to-equity ratio of 0.64. The business has a 50-day moving average price of $8.95 and a two-hundred day moving average price of $9.98. Fresenius SE & Co. KGaA has a 1-year low of $7.37 and a 1-year high of $14.81. The company has a market cap of $20.19 billion, a P/E ratio of 9.32 and a beta of 1.31.

Fresenius SE & Co. KGaA (OTCMKTS:FSNUYGet Rating) last issued its quarterly earnings results on Tuesday, February 22nd. The company reported $0.27 earnings per share for the quarter. Fresenius SE & Co. KGaA had a return on equity of 6.73% and a net margin of 4.85%. The firm had revenue of $11.40 billion during the quarter. Equities research analysts forecast that Fresenius SE & Co. KGaA will post 0.96 EPS for the current fiscal year.

A number of research analysts have recently commented on FSNUY shares. Berenberg Bank increased their price target on Fresenius SE & Co. KGaA from €55.95 ($60.16) to €60.25 ($64.78) and gave the company a “buy” rating in a research note on Wednesday, February 16th. JPMorgan Chase & Co. dropped their price target on Fresenius SE & Co. KGaA from €42.30 ($45.48) to €34.50 ($37.10) and set a “neutral” rating for the company in a research note on Thursday, February 24th. Credit Suisse Group dropped their price target on Fresenius SE & Co. KGaA from €43.00 ($46.24) to €35.00 ($37.63) and set a “neutral” rating for the company in a research note on Monday, February 28th. Societe Generale dropped their price target on Fresenius SE & Co. KGaA from €94.00 ($101.08) to €87.00 ($93.55) and set a “buy” rating for the company in a research note on Friday, February 25th. Finally, Deutsche Bank Aktiengesellschaft decreased their price objective on Fresenius SE & Co. KGaA from €38.00 ($40.86) to €36.00 ($38.71) and set a “hold” rating for the company in a report on Friday, February 25th. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, Fresenius SE & Co. KGaA has an average rating of “Buy” and a consensus price target of $44.35.

Fresenius SE & Co. KGaA Company Profile (Get Rating)

Fresenius SE & Co KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.

Further Reading

Receive News & Ratings for Fresenius SE & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.